FEARNS_PHARMACY_LTD - Accounts

Company Registration No. 04535871 (England and Wales)
FEARNS PHARMACY LTD
ANNUAL REPORT
AND UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JULY 2020
PAGES FOR FILING WITH REGISTRAR
FEARNS PHARMACY LTD
CONTENTS
Page
Statement of financial position
1 - 2
Notes to the financial statements
3 - 8
FEARNS PHARMACY LTD
STATEMENT OF FINANCIAL POSITION
AS AT 31 JULY 2020
31 July 2020
- 1 -
2020
2019
Notes
£
£
£
£
Non-current assets
Intangible assets
3
30,937
44,687
Property, plant and equipment
4
2,824
3,765
33,761
48,452
Current assets
Inventories
49,750
49,750
Trade and other receivables
5
224,714
301,151
Cash and cash equivalents
170,292
70
444,756
350,971
Current liabilities
6
(276,451)
(230,784)
Net current assets
168,305
120,187
Total assets less current liabilities
202,066
168,639
Non-current liabilities
7
(82,028)
(86,958)
Net assets
120,038
81,681
Equity
Called up share capital
100
100
Retained earnings
119,938
81,581
Total equity
120,038
81,681

The directors of the company have elected not to include a copy of the income statement within the financial statements.true

For the financial year ended 31 July 2020 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

FEARNS PHARMACY LTD
STATEMENT OF FINANCIAL POSITION (CONTINUED)
AS AT 31 JULY 2020
31 July 2020
- 2 -
The financial statements were approved by the board of directors and authorised for issue on 26 February 2021 and are signed on its behalf by:
Mr J Fearns
Director
Company Registration No. 04535871
FEARNS PHARMACY LTD
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JULY 2020
- 3 -
1
Accounting policies
Company information

Fearns Pharmacy Ltd is a private company limited by shares incorporated in England and Wales. The registered office is 78 Chorley New Road, Bolton, BL1 4BY.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Revenue

Revenue is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

 

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

1.3
Intangible fixed assets - goodwill

Goodwill represents the excess of the cost of acquisition of unincorporated businesses over the fair value of net assets acquired. It is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is considered to have a finite useful life and is amortised on a systematic basis over its expected life, which is 20 years.

 

1.4
Property, plant and equipment

Property, plant and equipment are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Fixtures, fittings & equipment
25% reducing balance
Motor vehicles
25% straight line

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

FEARNS PHARMACY LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JULY 2020
1
Accounting policies
(Continued)
- 4 -
1.5
Impairment of non-current assets

At each reporting period end date, the company reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

 

1.6
Inventories

Inventories are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the inventories to their present location and condition.

 

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of inventories over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.7
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.8
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's statement of financial position when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include trade and other receivables and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

FEARNS PHARMACY LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JULY 2020
1
Accounting policies
(Continued)
- 5 -
Basic financial liabilities

Basic financial liabilities, including trade and other payables, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

 

Trade payables are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade payables are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

1.9
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.10
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the income statement because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

 

1.11
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or non-current assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

 

1.12
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.13
Leases
FEARNS PHARMACY LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JULY 2020
1
Accounting policies
(Continued)
- 6 -

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leases asset are consumed.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2020
2019
Number
Number
Total
7
7
3
Intangible fixed assets
Goodwill
£
Cost
At 1 August 2019 and 31 July 2020
275,000
Amortisation and impairment
At 1 August 2019
230,313
Amortisation charged for the year
13,750
At 31 July 2020
244,063
Carrying amount
At 31 July 2020
30,937
At 31 July 2019
44,687
FEARNS PHARMACY LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JULY 2020
- 7 -
4
Property, plant and equipment
Fixtures, fittings & equipment
Motor vehicles
Total
£
£
£
Cost
At 1 August 2019 and 31 July 2020
41,153
7,999
49,152
Depreciation and impairment
At 1 August 2019
37,388
7,999
45,387
Depreciation charged in the year
941
-
0
941
At 31 July 2020
38,329
7,999
46,328
Carrying amount
At 31 July 2020
2,824
-
0
2,824
At 31 July 2019
3,765
-
0
3,765
5
Trade and other receivables
2020
2019
Amounts falling due within one year:
£
£
Trade receivables
92,745
184,677
Other receivables
31,969
16,474
Associated company loan
100,000
100,000
224,714
301,151
6
Current liabilities
2020
2019
£
£
Bank overdraft
-
0
3,982
Trade payables
180,406
190,220
Taxation and social security
37,075
29,951
Other payables
58,970
6,631
276,451
230,784
7
Non-current liabilities
2020
2019
£
£
Other payables
82,028
86,958
FEARNS PHARMACY LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JULY 2020
- 8 -
8
Operating lease commitments
Lessee

The company is committed to pay £15,000 per annum for the lease of property. The lease terminates on 31 August 2024.

At the reporting end date the company had outstanding commitments for future minimum lease payments under non-cancellable operating leases, as follows:

2020
2019
£
£
Lease of property
61,250
76,250
2020-07-312019-08-01false26 February 2021CCH SoftwareCCH Accounts Production 2021.100No description of principal activityMr J FearnsMr M J Fearns045358712019-08-012020-07-31045358712020-07-3104535871core:NetGoodwill2020-07-3104535871core:NetGoodwill2019-07-31045358712018-08-012019-07-31045358712019-07-3104535871core:FurnitureFittings2020-07-3104535871core:MotorVehicles2020-07-3104535871core:FurnitureFittings2019-07-3104535871core:MotorVehicles2019-07-3104535871core:CurrentFinancialInstrumentscore:WithinOneYear2020-07-3104535871core:CurrentFinancialInstrumentscore:WithinOneYear2019-07-3104535871core:Non-currentFinancialInstrumentscore:AfterOneYear2020-07-3104535871core:Non-currentFinancialInstrumentscore:AfterOneYear2019-07-3104535871core:CurrentFinancialInstruments2020-07-3104535871core:CurrentFinancialInstruments2019-07-3104535871core:ShareCapital2020-07-3104535871core:ShareCapital2019-07-3104535871core:RetainedEarningsAccumulatedLosses2020-07-3104535871core:RetainedEarningsAccumulatedLosses2019-07-3104535871bus:Director12019-08-012020-07-3104535871core:Goodwill2019-08-012020-07-3104535871core:FurnitureFittings2019-08-012020-07-3104535871core:MotorVehicles2019-08-012020-07-3104535871core:NetGoodwill2019-07-3104535871core:NetGoodwill2019-08-012020-07-3104535871core:FurnitureFittings2019-07-3104535871core:MotorVehicles2019-07-31045358712019-07-3104535871core:Non-currentFinancialInstruments2020-07-3104535871core:Non-currentFinancialInstruments2019-07-3104535871bus:PrivateLimitedCompanyLtd2019-08-012020-07-3104535871bus:SmallCompaniesRegimeForAccounts2019-08-012020-07-3104535871bus:FRS1022019-08-012020-07-3104535871bus:AuditExemptWithAccountantsReport2019-08-012020-07-3104535871bus:Director22019-08-012020-07-3104535871bus:FullAccounts2019-08-012020-07-31xbrli:purexbrli:sharesiso4217:GBP